Everolimus

Generic Name: Everolimus

Brand Names: Afinitor, Votubia, Zortress

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₃NO_₁₄

CAS Number: 159351-69-6

Unique Ingredient Identifier: 9HW64Q8G6G

Background: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication: Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions: Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors

Associated Therapies: -

Clinical Trials

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Phase 2

Conditions: Gallbladder Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct

Interventions: Procedure: biological test
Drug: GEMOX
Drug: Cetuximab
Drug: Trastuzumab
Drug: Gefitinib
Drug: Lapatinib
Drug: Everolimus
Drug: Sorafenib
Drug: Crizotinib

First Posted Date: 2016-07-19

Last Posted Date: 2018-05-07

Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 152

Registration Number: NCT02836847

Locations: 🇨🇳
Xinhua Hospital, Shanghai, Shanghai, China

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

First Posted Date: 2016-06-24

Last Posted Date: 2023-05-30

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 460

Registration Number: NCT02813135

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇳🇱
Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands

and more 4 locations

Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT

Phase 2

Completed

Conditions: Graft-versus-Host Disease

Interventions: Drug: Everolimus

First Posted Date: 2016-06-24

Last Posted Date: 2021-03-17

Lead Sponsor: University of Cologne

Target Recruit Count: 19

Registration Number: NCT02812940

Locations: 🇩🇪
University of Cologne, Cologne, Germany

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Phase 3

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Lenvatinib
Drug: Sunitinib
Drug: Everolimus
Drug: Pembrolizumab

First Posted Date: 2016-06-23

Last Posted Date: 2024-11-01

Lead Sponsor: Eisai Inc.

Target Recruit Count: 1069

Registration Number: NCT02811861

Locations: 🇮🇱
Chaim Sheba Medical Center, Ramat-Gan, Israel
🇯🇵
Facility #2, Tokyo, Japan
🇺🇸
Mount Sinai Medical Center, Miami Beach, Florida, United States

and more 159 locations

Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)

Completed

Conditions: Breast Cancer
Renal Cell Carcinoma

First Posted Date: 2016-06-22

Last Posted Date: 2017-10-16

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 75

Registration Number: NCT02809404

Locations: 🇳🇱
Radboud university medical center, Nijmegen, Netherlands

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Everolimus
Drug: Fluorouracil
Drug: Letrozole
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2016-04-18

Last Posted Date: 2021-09-23

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 40

Registration Number: NCT02742051

Locations: 🇨🇳
Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University, Guangzhou, Guangdong, China

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: Everolimus
Drug: Exemestane

First Posted Date: 2016-04-08

Last Posted Date: 2021-05-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 104

Registration Number: NCT02732119

Locations: 🇺🇸
Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
St. Luke's Cancer Institute Regulatory, Kansas City, Missouri, United States
🇺🇸
Research Medical Center HCA Midwest Division, Kansas City, Missouri, United States

and more 22 locations

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Phase 2

Completed

Conditions: Clear-cell Metastatic Renal Cell Carcinoma

Interventions: Drug: MLN0128
Drug: Everolimus
Drug: MLN1117

First Posted Date: 2016-03-31

Last Posted Date: 2021-11-19

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 96

Registration Number: NCT02724020

Locations: 🇮🇹
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy
🇫🇷
Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, Paris, France

and more 33 locations

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Phase 1

Completed

Conditions: Renal Transplant
Adult Living Donor Kidney Transplant Recipients
Kidney Transplant
Living Kidney Donor

Interventions: Biological: Polyclonal Regulatory T Cells
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Drug: Everolimus
Drug: Mycophenolic acid
Drug: Acetaminophen
Drug: Diphenhydramine
Procedure: Biopsy, Kidney
Procedure: Blood Draw
Procedure: Leukapheresis
Procedure: IS regimen conversion

First Posted Date: 2016-03-17

Last Posted Date: 2024-10-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 32

Registration Number: NCT02711826

Locations: 🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Colorado Health Transplant Center - Anschutz, Aurora, Colorado, United States

and more 3 locations

Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Phase 2

Active, not recruiting

Conditions: Neuroendocrine Carcinoma

Interventions: Drug: Everolimus

First Posted Date: 2016-02-22

Last Posted Date: 2023-05-30

Lead Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

Target Recruit Count: 30

Registration Number: NCT02687958

Locations: 🇮🇹
U.O. Oncologia Medica 1 - AOU Pisana, Pisa, Tuscany, Italy
🇮🇹
S.C. Oncologia - Policlinico, Modena, Emilia - Romagna, Italy
🇮🇹
Azienda Ospedaliera "Spedali Civili di Brescia", Brescia, Italy

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy